An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics

NCT ID: NCT00448630

Last Updated: 2022-05-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

328 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-10-23

Study Completion Date

2008-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sampling Method Details: Group of patients using the same atypical anti-psychotic.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Metabolic Syndrome X

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atypical Antispychotics (or second generation antipsychotics)

Patients with schizophrenia who are currently receiving or are going to start a new treatment with atypical antipsychotics, ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, amisulpride.

No intervention

Intervention Type OTHER

Non-interventional study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Non-interventional study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female and male patients diagnosed as schizophrenia by the Diagnostic and Statistical Manual of Mental Disorders.
* Age between 18-45 years
* Patients who started atypical antipsychotic drug treatment or patients who switched from the previous conventional or atypical antipsychotic treatment to another atypical antipsychotic drug treatment by the decision of their physicians.

Exclusion Criteria

* Patients who are pregnant or considering pregnancy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Adana Psychiatry and Neurology Hospital

Kurttepe, Adana, Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Kurttepe, Adana, Turkey (Türkiye)

Site Status

Adana Psychiatry and Neurology Hospital

Adana, , Turkey (Türkiye)

Site Status

Cukurova University Scool of Medicine

Adana, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Adana, , Turkey (Türkiye)

Site Status

Ankara Oncology Research and Training Hospital

Ankara, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Ankara, , Turkey (Türkiye)

Site Status

Ankara Diskapi Training and Research Hospital

Ankara, , Turkey (Türkiye)

Site Status

Ankara Numune Research Hospital

Ankara, , Turkey (Türkiye)

Site Status

Ankara Numune Training and Research Hospital Department of Psychiatry

Ankara, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Ankara, , Turkey (Türkiye)

Site Status

Antakya Mustafa Kemal University School of Medicine

Antakya, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Antakya, , Turkey (Türkiye)

Site Status

Bolu Psychiatry and Neurology Hospital

Bolu, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Bolu, , Turkey (Türkiye)

Site Status

Pamukkale University School Of Medicine

Denizli, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Denizli, , Turkey (Türkiye)

Site Status

Elazig Mental Illness And Diseases Hospital

Elâzığ, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Elâzığ, , Turkey (Türkiye)

Site Status

Eskisehir Osmangazi University

Eskişehir, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Eskişehir, , Turkey (Türkiye)

Site Status

Bakirkoy Psychiatry and Neurology Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Istanbul, , Turkey (Türkiye)

Site Status

Bakirkoy Mental Health Hospital, First Clinic of Neurosis

Istanbul, , Turkey (Türkiye)

Site Status

Bakirkoy Psychiatry and Neurology Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Cerrahpasa School of Medicine

Istanbul, , Turkey (Türkiye)

Site Status

Erenkoy Psychology and neurology hospital

Istanbul, , Turkey (Türkiye)

Site Status

Istanbul University Istanbul School of Medicine

Istanbul, , Turkey (Türkiye)

Site Status

Marmara School of Medicine

Istanbul, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Istanbul, , Turkey (Türkiye)

Site Status

Sisli Etfal Research and training Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Vakif Gureba Hospital, Department of Psychiatry

Istanbul, , Turkey (Türkiye)

Site Status

Ege University School Of Medicine

Izmir, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Izmir, , Turkey (Türkiye)

Site Status

Kayseri Public Hospital

Kayseri, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Kayseri, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Konya, , Turkey (Türkiye)

Site Status

Selcuk University Medical School Department of Psychiatry

Konya, , Turkey (Türkiye)

Site Status

Manisa Mental Illness And Diseases Hospital

Manisa, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Manisa, , Turkey (Türkiye)

Site Status

19 may University School of Medicine

Samsun, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Samsun, , Turkey (Türkiye)

Site Status

Samsun Mental Illness And Diseases Hospital

Samsun, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Trabzon, , Turkey (Türkiye)

Site Status

Trabzon Numune Research Hospital

Trabzon, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Trakya, , Turkey (Türkiye)

Site Status

Trakya University School of Medicine

Trakya, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A1281160

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.